Alpine Immune Sciences (NASDAQ: ALPN) is a promising player in the Biotechnology industry, with a potential upside of 5.99%
and a 52-week high of $16.25. The company's stock has shown a positive price change of $1.35, with an open price of $14.72, indicating a bullish trend. However, investors should be aware of the company's high coefficient of variation at 1.6K
and a standard deviation of 6.02, suggesting a high level of risk and volatility. Additionally, the company is expected to report a loss of $0.4 per share in the next quarter. Despite these risks, the Jensen Alpha of 0.512 and Treynor Ratio of 0.1334 indicate a potential for high returns relative to the risk taken.
More than 87.0% of Alpine Immune Sciences shares are held by institutions such as insurance companies. The institutional ownership of Alpine Immune Sciences refers to the portion of Alpine Immune Sciences equity owned by entities like mutual funds, pension funds, insurance companies, investment firms, foundations, or other large organizations that manage money on behalf of others. For our latest analysis of Alpine, including its current ownership diagnostics, please refer to the provided link.
There are currently many different techniques concerning forecasting the market as a whole as well as predicting
future values of individual securities such as Alpine Immune Sciences. Regardless of method or technology, to accurately forecast the stock or bond market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment
and impact your forecasting results.
Predictive Modules for Alpine Immune
Sophisticated investors, who have witnessed many market ups and downs
, frequently view the market will even out over time. This tendency of Alpine Immune's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy. Please use the tools below to analyze the current value of Alpine Immune in the context of predictive analytics.
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Alpine Immune. Your research has to be compared to or analyzed against Alpine Immune's peers to derive any actionable benefits. When done correctly, Alpine Immune's competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy toward taking a position in Alpine Immune Sciences.
How important is Alpine Immune's Liquidity
Alpine Immune financial leverage
refers to using borrowed capital as a funding source to finance Alpine Immune Sciences ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Alpine Immune financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Financial leverage can amplify the potential profits to Alpine Immune's owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if the firm cannot cover its debt costs. The degree of Alpine Immune's financial leverage can be measured in several ways, including by ratios such as the debt-to-equity ratio (total debt / total equity), equity multiplier (total assets / total equity), or the debt ratio (total debt / total assets). Please check the breakdown
between Alpine Immune's total debt and its cash.
Alpine Immune Gross Profit
Alpine Immune Gross Profit growth is one of the most critical measures in evaluating the company. The Gross Profit growth rate is calculated simply by comparing Alpine Immune previous period's values with its current period's values. Each time period you're measuring should be of equal lengths the increase or decrease, in a company's Gross Profit between two periods. Here we show Alpine Immune Gross Profit growth over the last 10 years. Please check Alpine Immune's gross profit
and other fundamental indicators
for more details.
Going after Alpine Financials
Alpine Immune Sciences is displaying above-average volatility over the selected time horizon. Investors should scrutinize Alpine Immune Sciences independently to ensure intended market timing strategies are aligned with expectations about Alpine Immune volatility. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Alpine Immune's stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Alpine Immune's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.
|Return on Investment
|Return on Assets
|Return on Equity
|Return on Sales
"Never invest in a business you cannot understand," is a well-known financial proverb that rings true when considering the future growth of Alpine Immune Sciences (NASDAQ: ALPN).
With a market capitalization of 790.67M
and a healthy cash and equivalents balance of 167.86M
, the company appears to be in a strong financial position. Insiders own 6.41% of the company, indicating a certain level of confidence in the company's prospects. However, the company's EPS estimates for the next quarter and current year are projected at losses of 0.4 and 1.2 respectively, suggesting that profitability may not be imminent. Despite this, Wall Street's target price for ALPN is 18.29, indicating potential upside. The company's Z Score of 32.5 also suggests a low probability of bankruptcy. Therefore, while the company's financials indicate some risk, insiders and Wall Street analysts appear bullish on Alpine Immune Sciences' future growth. .
Alpine Immune implied volatility may change after the roll up
The stock volatility of Alpine Immune Sciences may be set for a shift following the roll-up, as indicated by the recent drop in skewness to 4.47. This shift suggests a decrease in the asymmetry of the stock's return distribution, which could potentially modify the risk-reward profile for investors. Both traders and investors should closely monitor this metric, as it could hint at an impending change in the stock's implied volatility, thereby influencing investment strategies and decisions. Alpine Immune Sciences has exhibited above-average volatility over the chosen time period. Investors should thoroughly analyze Alpine Immune Sciences independently to ensure that their intended market timing
strategies align with their expectations about Alpine Immune's volatility. Understanding different market volatility
trends can often assist investors in timing the market. Proper use of volatility indicators allows traders to gauge Alpine Immune's stock risk against market volatility during both bullish and bearish trends. The heightened level of volatility that accompanies bear markets can directly affect Alpine Immune's stock price
, adding stress to investors as they watch the value of their shares plummet.
This typically compels investors to rebalance their portfolios by purchasing different stocks as prices drop. In conclusion, the financial outlook for Alpine Immune Sciences (ALPN) is promising. With a market value of 16.07
and a real value of 17.5
, the company is showing strong potential for growth. The positive analyst consensus, with 7 strong buys and an overall recommendation to buy, further supports this view. The estimated target price ranges from 16 to 22, with an average estimated value of 18.285, suggesting a potential upside for investors. However, as with any investment, it's crucial to consider the company's fiscal year-end results in December and the valuation hype value of 15.98. All in all, ALPN is an investment opportunity that is worth considering for those looking to diversify their portfolio in the biotechnology sector. .
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.Try AI Portfolio Architect
for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to email@example.com